الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 117 |  |  |
| | | from | 117 | | |
Abstract
This study was designed to compare the gastrointestinal side effects of non-selective and selective non-steroidal anti-inflammatory drugs.
In this cross-sectional study, we studied 4 groups of patients:
Group I: Control group: including 10 healthy volunteers suffering from dyspepsia symptom and divided into 5 males and 5 females.
Test groups: including the following three groups:
Group II: including 10 osteoarthritis and rheumatic patients receiving 1200mg/ day of Ibuprofen from at least one month and divided into 5 males and 5 females
Group III: including 10 osteoarthritis and rheumatic patients receiving 200-400 mg/day of Celecoxib from at least one month and divided into 5 males and 5 females
Group IV: including 10 osteoarthritis and rheumatic patients receiving 7.5-15 mg/day of Meloxicam from at least one month and divided into 5 males and 5 females
All subjects of control group and the three test groups were submitted to the following: through history, medical and neurological examination and upper endoscopy.
Results of this study showed that:
• The endoscopy conclusion was dyspepsia for all the healthy volunteers indicating that their problem was due to the dyspepsia.
• In group II (Ibuprofen group), the report of the upper endoscopy showed that there were 2 patients suffering from dyspepsia, 3 patients suffering from gastritis and 5 patients suffering from ulcer.
• In group III (Celecoxib group), from the conclusion of the upper endoscopy, it was concluded that 4 patients were suffering from dyspepsia, 4 patients were suffering from gastritis and 2 patients were suffering from ulcer.
• Concerning to group IV (Meloxicam group), there were 3 patients suffering from dyspepsia, 4 patients suffering from gastritis and 3 patients suffering from ulcer.
Results revealed that:
• There was a statistically highly significant difference between the studied groups regarding the incidence of dyspepsia (P-value=0.008).
• There was another statistically significant difference between the studied groups regarding the incidence of gastritis (P-value=0.042).
• There was no statistically significant difference between the studied groups regarding the incidence of ulcer (P-value=0.333).
• There was a statistically highly significant difference between group I (Control group) and group II (Ibuprofen group) regarding the percent of incidence of dyspepsia (P-value=0.001).
• There was another statistically significant difference between these two groups regarding the percent of incidence of ulcer (P-value=0.012).
• There was no statistically significant difference between these two groups regarding the percent of incidence of gastritis (P-value=0.067).
• There was no statistically significant difference between group II (Ibuprofen group) and group III (Celecoxib group) regarding the percent of incidence of dyspepsia (P-value=0.342) or regarding the percent of incidence of gastritis (P-value=0.648) or regarding the percent of incidence of ulcer (P-value=0.170).
• There was no statistically significant difference between group III (Celecoxib group) and group IV (Meloxicam group) regarding the percent of incidence of dyspepsia (P-value=0.648) or regarding the percent of incidence of gastritis (P-value=1) or regarding the percent of incidence of ulcer (P-value=0.615).
• There was a statistically highly significant difference between group I (Control group) and group III (Celecoxib group) regarding the percent of incidence of dyspepsia (P-value=0.004).
• There was another statistically significant difference between them regarding the percent of incidence of gastritis (P-value=0.029).
• There was no statistically significant difference between them regarding the percent of incidence of ulcer (P-value=0.146).
• There was a statistically highly significant difference between group I (Control group) and group IV (Meloxicam group) regarding the percent of incidence of dyspepsia (P-value=0.001).
• There was another statistically significant difference between them regarding the percent of incidence of gastritis (P-value=0.029).
• There was no statistically significant difference between them regarding the percent of incidence of ulcer (P-value=0.067).
• There was no statistically significant difference between group II (Ibuprofen group) and group IV (Meloxicam group) regarding the percent of incidence of dyspepsia (P-value=0.615) or regarding the percent of incidence of gastritis (P-value=0.648) or regarding the percent of incidence of ulcer (P-value=0.374) .
• There was no statistically significant correlation between the age in the three test studied groups with the incidence of dyspepsia or gastritis or ulcer .
• In group II, There was no statistically significant correlation between the daily dose of Ibuprofen and the incidence of dyspepsia or gastritis or ulcer.
• In group III and group IV, there was no statistically significant correlation between the daily dose of Celecoxib or Meloxicam with the incidence of dyspepsia or gastritis or ulcer .
• In group II, There was no statistically significant correlation between the daily dose of Ibuprofen per weight and the incidence of dyspepsia or gastritis or ulcer.
• In group III and group IV, there was no statistically significant correlation between the daily dose of Celecoxib or Meloxicam per weight with the incidence of dyspepsia or gastritis or ulcer .
• In group II, There was a statistically significant correlation between the duration of administration of Ibuprofen and the incidence of dyspepsia, but there was no a statistically significant correlation between the duration of administration of Ibuprofen and the incidence of gastritis or ulcer.
• In group III, there was a statistically significant correlation between the duration of administration of Celecoxib the incidence of dyspepsia, but there was no statistically significant correlation between the duration of administration of Celecoxib and the incidence of gastritis or ulcer.
• In group IV, there was no statistically significant correlation between the duration of administration of Meloxicam and the incidence of dyspepsia or gastritis or ulcer.